Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11558761 | 1.00 | MAOA (0.48) | MAOAMAOBGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6462848 | 0.85 | KDM1A (0.35) | KDM1A | |
| SCHEMBL6460757 | 0.81 | KCNH2 (0.41) | MAOAMAOB | |
| SCHEMBL27684743 | 0.79 | HTT (0.45) | MAOAMAOBGRIN2DGRIN3BGRIN1 | |
| SCHEMBL24816872 | 0.78 | HPGD (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4057756 | 0.77 | LMNA (0.44) | MAOAMAOBGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11481803 | 0.76 | GRIN1 (0.42) | MAOAMAOBGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2488141 | 0.76 | MAOA (0.40) | MAOAMAOBGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8087689 | 0.76 | MAOA (0.44) | MAOAMAOBGRIN1GRIN2AGRIN2B | |
| SCHEMBL9834891 | 0.73 | MAOA (0.46) | MAOAMAOBKDM1AHTTDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | MAOA 45/4885MAOB 37/4885GRIN2D 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.